玻璃体腔抗VEGF治疗与渗出型AMD患者卒中、心肌梗死及死亡风险的关联
这项基于人群的回顾性队列研究纳入504例接受玻璃体腔抗VEGF注射的渗出型AMD患者,并与三个年龄性别匹配的对照组比较。结果显示抗VEGF治疗与卒中或心肌梗死风险无一致增加,仅与抗VEGF前时代渗出型AMD对照相比死亡风险增加(HR 1.63,95%CI 1.30-2.04,P<.001),提示心脏事件可能不归因于抗VEGF治疗。
要点
- 抗VEGF治疗未一致增加卒中或心肌梗死风险。
- 5年卒中风险7.2%、心肌梗死风险6.1%、死亡风险30.0%。
- 仅与抗VEGF前时代渗出型AMD对照相比死亡风险增加(HR 1.63)。
核心结论
- 玻璃体腔抗VEGF治疗渗出型AMD与卒中、心肌梗死或死亡风险的一致增加无关。
- 患者经历的心脏事件可能不归因于抗VEGF治疗。
研究设计与样本
- 采用Kaplan-Meier和多因素Cox比例风险回归模型评估5年卒中、心肌梗死和死亡风险。
主要发现
- 504例患者中女性321例(63.7%),平均(SD)年龄76.5(10.0)岁。
- Kaplan-Meier分析显示5年卒中风险7.2%、心肌梗死风险6.1%、死亡风险30.0%。
- 与干性AMD对照、渗出型AMD对照或无AMD对照相比,抗VEGF治疗未增加卒中或心肌梗死风险。
- 多因素分析显示与抗VEGF前时代渗出型AMD对照相比死亡风险增加(HR 1.63;95%CI 1.30-2.04;P<.001),与其他对照组相比未增加。
关键数值与推荐
- 5年卒中风险7.2%、心肌梗死风险6.1%、死亡风险30.0%(504例接受抗VEGF治疗的渗出型AMD患者)。
- 与抗VEGF前时代渗出型AMD对照相比死亡风险HR 1.63(95%CI 1.30-2.04;P<.001)。
临床怎么用
- 为渗出型AMD患者进行抗VEGF治疗时,卒中或心肌梗死风险未见一致增加,可据此进行患者沟通。
- 与抗VEGF前时代渗出型AMD患者相比死亡风险增加,需关注该人群的全身健康状况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Current studies assessing the risk of stroke, myocardial infarction (MI), and death in patients undergoing intravitreal anti-vascular endothelial growth factor (VEGF) therapy are inconclusive. To our knowledge, no population-based studies have been performed to examine these potential risks. OBJECTIVE: To examine whether patients with exudative age-related macular degeneration (AMD) receiving intravitreal anti-VEGF injections have a higher incidence of MI, stroke, or death compared with control populations. DESIGN, SETTING, AND PARTICIPANTS: This population-based, retrospective cohort study included 504 patients from Olmsted County, Minnesota, identified through the Rochester Epidemiology Project (REP) database as receiving at least 1 intravitreal anti-VEGF injection for exudative AMD from January 1, 2004, to December 31, 2013. Three age- and sex-matched control groups of individuals who did not receive anti-VEGF treatment and were derived from the REP database were also studied: control individuals with exudative AMD in the era before anti-VEGF (January 1, 1990, to December 31, 2003), controls with dry AMD, and controls without AMD. Data analysis was performed from September 1, 2016, to September 1, 2017. MAIN OUTCOMES AND MEASURES: Five-year risk of stroke, MI, and death were assessed in patients compared with controls using Kaplan-Meier and multivariate analysis with Cox proportional hazards regression models. RESULTS: The study included 504 patients (321 female [63.7%]; mean [SD] age, 76.5 [10.0] years) who received at least 1 intravitreal anti-VEGF injection for exudative AMD during the study period. Kaplan-Meier analysis revealed a 5-year risk of 7.2% for stroke, 6.1% for MI, and 30.0% for death. Patients who received anti-VEGF had no increased risk of stroke or MI compared with controls with dry AMD (n = 504), controls with exudative AMD (n = 473), or controls without AMD (n = 504). There was an increased risk of mortality compared with controls with exudative AMD in the era prior to anti-VEGF therapy but not the other control groups on multivariate analysis (hazard ratio, 1.63; 95% CI, 1.30-2.04; P < .001). CONCLUSIONS AND RELEVANCE: This population-based study revealed that intravitreal anti-VEGF therapy for exudative AMD was not associated with consistent increases in the risk of stroke, MI, or death compared with no therapy in patients with or without AMD. It appears to be likely the cardiac events these patients experience are not attributable to their anti-VEGF therapy.
引用
- Dalvin LA, Starr MR, AbouChehade JE, et al. Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration. JAMA Ophthalmol. 2019. PMID: 30703203. doi:10.1001/jamaophthalmol.2018.6891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。